La cadena de opciones muestra datos clave de las opciones de acciones de ZHONGCHAO a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para ZHONGCHAO..

ZHONGCHAO (NASDAQ:ZCMD) Bolsa, Cadena de Opciones

ZHONGCHAO Inc is a Cayman Islands-based provider of healthcare information, education, and training services. It provides services to healthcare professionals and the public in China. It offers online and onsite health information services, healthcare education programs, and healthcare training products, consisting of clinical practice training, open classes of popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content.

ZHONGCHAO Inc

TSLA: -6% &#x7C; <a href="https://www.benzinga.com//node/42613402">NHTSA Announced Earlier, Tesla Recalls 2024 Cybertruck, 2017-2025 Model 3, And 2020-2025 Model Y For TPMS Warning Light Issue; OTA Fix Released, Owner Notification Letters To Be Mailed Feb. 15, 2025</a>
&nbsp;
NKE: -6% &#x7C; <a href="https://www.benzinga.com//node/42605414">Nike Q2 Earnings: Revenue Beat, EPS Beat, Shares Jump, and then reverse — 'Nike Being Nike Again'</a>
&nbsp;
HUMA: 91% &#x7C; <a href="https://www.benzinga.com//node/42609617">FDA Approves Humacyte's SYMVESS For Treating Extremity Vascular Injuries</a>

Movers

Trading Ideas

HUMA

TSLA

Market-Moving News for December 20th

On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, genetic form of severe hypertriglyceridemia (SHTG) that can <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42607141/tryngolza-olezarsen-approved-in-u-s-as-first-ever-treatment-for-adults-living-with-familial-chylom" rel="noreferrer noopener">lead to acute pancreatitis (AP)</a>.
SHTG is&nbsp;a condition where the level of triglycerides (type of fat) in the blood is more than three times the normal level.&nbsp;
Tryngolza is the first-ever&nbsp;FDA-approved treatment that significantly and substantially reduces&nbsp;triglyceride levels in adults with FCS and provides a clinically meaningful reduction in AP events when used with an appropriate diet (≤20 grams of fat per day).
Tryngolza is self-administered via an auto-injector once-monthly.
The FDA approval was based on Phase 3 Balance trial data in adult patients.
In the Balance study, Tryngolza 80 mg demonstrated a statistically significant placebo-adjusted mean reduction in triglyceride levels of 42.5% from baseline to six months (p=0.0084).&nbsp;
Reductions from baseline to 12 months were further improved, with Tryngolza achieving a placebo-adjusted 57% mean triglyceride reduction.&nbsp;
Tryngolza also demonstrated a substantial, clinically meaningful reduction in AP events over 12 months; one patient (5%) experienced one episode of AP in the Tryngolza group compared with seven patients (30%) who experienced 11 total episodes of AP in the placebo group.&nbsp;
Tryngolza will be available in the U.S. before year end.
Olezarsen is currently being evaluated in three Phase 3 clinical trials – CORE, CORE2, and ESSENCE – for SHTG. Olezarsen has not been reviewed or approved for SHTG.
In November, Ionis Pharmaceuticals announced the pivotal Phase 3 study design following alignment with the FDA on ION582 for Angelman syndrome (AS). The trial is expected to start in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41769886/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome" rel="noreferrer noopener">the first half of 2025</a>.
AS typically presents in infancy and is characterized by profound intellectual disability, impaired verbal abilities, and severe motor impairment.
Price Action: At last check on Friday, IONS stock was up 3.79% at $36.94 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42600482/mercks-investigational-two-drug-regime-for-hiv-meets-primary-goal-in-two-late-stage-trials" target="_blank" rel="noreferrer noopener">Merck&#8217;s Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials</a></li>
</ul>

Biotech

News

Health Care

General

IONS

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

JP Morgan analyst Michael Mueller upgrades Federal Realty Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRT#NYSE">FRT</a>) from Neutral to Overweight and raises the price target from $122 to $125.

Upgrades

Price Target

Analyst Ratings

JP Morgan Upgrades Federal Realty Investment to Overweight, Raises Price Target to $125

Further information regarding the final result of the offer, including the number of shares tendered, will be disclosed in JBT's upcoming 8-K filing.

JBT Says Voluntary Takeover Offer For Marel hf. Expired; Has Now Satisfied All Conditions To Offer, Including Minimum Acceptance Condition

JP Morgan analyst Anthony Paolone upgrades Kilroy Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRC#NYSE">KRC</a>) from Neutral to Overweight and raises the price target from $45 to $49.

JP Morgan Upgrades Kilroy Realty to Overweight, Raises Price Target to $49

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Oruka Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with a Buy and maintains $45 price target.

Reiteration

ORKA

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $45 Price Target

Mizuho analyst David Bellinger maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Neutral and raises the price target from $72 to $80.

Mizuho Maintains Neutral on CarMax, Raises Price Target to $80

JP Morgan analyst Anthony Paolone downgrades Kimco Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIM#NYSE">KIM</a>) from Overweight to Neutral and announces $26 price target.

Downgrades

JP Morgan Downgrades Kimco Realty to Neutral, Announces $26 Price Target

Needham analyst Joseph Stringer maintains Ionis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) with a Buy and maintains $60 price target.

Needham Maintains Buy on Ionis Pharmaceuticals, Maintains $60 Price Target

TAOP

Taoping Announced That It Received Notification From The Nasdaq Stock Market Confirming The Company Has Been Granted An Additional 180 Calendar Day Period For Compliance Under Its Minimum Bid Price Requirement Through June 16, 2025

JP Morgan analyst Michael Mueller downgrades Healthcare Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HR#NYSE">HR</a>) from Overweight to Neutral and announces $19 price target.

JP Morgan Downgrades Healthcare Realty Trust to Neutral, Announces $19 Price Target

JP Morgan analyst Michael Mueller downgrades Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) from Overweight to Neutral and lowers the price target from $78 to $75.

LINE

JP Morgan Downgrades Lineage to Neutral, Lowers Price Target to $75

HC Wainwright &amp; Co. analyst Arthur He maintains LAVA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVTX#NASDAQ">LVTX</a>) with a Buy and lowers the price target from $6 to $2.

LVTX

HC Wainwright & Co. Maintains Buy on LAVA Therapeutics, Lowers Price Target to $2

Contracts

AECOM Says Awarded Several New Positions On Additional AMP8 UK Water Infrastructure Frameworks

SBC Medical Group Holdings Says Its Unit SBC Medical Group Co. Has Decided To Sell All Shares Of Its Subsidiaries, SBC Kijimadaira Resort Co And Skynet Academy Co

XCharge said it is committed to sound corporate governance and transparent communication with its shareholders. The Company's operations continue as normal, and its financial condition remains strong.
 &nbsp;

XCHG Says It Is Not Aware Of Any Material News Or Events That Would Account For Unusual Trading Activity

<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">December 17, 2024 NHTSA CAMPAIGN NUMBER: 24V935000</a>
<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">TPMS Light May Not Remain Illuminated/FMVSS 138</a>
<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">Software Update Repairs Recall</a>
<a href="https://www.nhtsa.gov/search-safety-issues#recall_43">Driving with improperly inflated tires increases the risk of a crash.</a>
NHTSA Campaign Number:&nbsp;24V935000
Manufacturer&nbsp;Tesla, Inc.
Components&nbsp;TIRES
Potential Number of Units Affected&nbsp;694,304
Summary
Tesla, Inc. (Tesla) is recalling certain 2024 Cybertruck, 2017-2025 Model 3, and 2020-2025 Model Y vehicles. The tire pressure monitoring system (TPMS) warning light may not remain illuminated between drive cycles, failing to warn the driver of low tire pressure. As such, these vehicles fail to comply with the requirements of Federal Motor Vehicle Safety Standard number 138, "Tire Pressure Monitoring Systems."
Remedy
Tesla released an over-the-air (OTA) software update, free of charge. Owner notification letters are expected to be mailed February 15, 2025. Owners may contact Tesla customer service at 1-877-798-3752. Tesla's number for this recall is SB-24-00-018.
Notes
Owners may also contact the National Highway Traffic Safety Administration Vehicle Safety Hotline at 1-888-327-4236 (TTY 1-800-424-9153), or go to <a href="http://www.nhtsa.gov" title="www.nhtsa.gov">www.nhtsa.gov</a>.

NHTSA Announced Earlier, Tesla Recalls 2024 Cybertruck, 2017-2025 Model 3, And 2020-2025 Model Y For TPMS Warning Light Issue; OTA Fix Released, Owner Notification Letters To Be Mailed Feb. 15, 2025

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) chief Hock Tan expressed enormous conviction over the sustainability of the <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">artificial intelligence frenzy</a> as Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google, Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and TikTok parent ByteDance splurged on designing custom processors that accelerate training and deployment of AI systems, the Financial Times reports.
Reportedly, OpenAI and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) also tapped Broadcom to develop their AI server chips to diversify their exposure to Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Broadcom stock has surged over 101% year-to-date.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/downgrades/24/12/42561430/match-group-analyst-flags-tinder-woes-industry-challenges-for-stock-downgrade" rel="noreferrer noopener">Match Group Analyst Flags Tinder Woes, Industry Challenges For Stock Downgrade</a>
Tan <a target="_blank" href="https://www.ft.com/content/5b4160b7-6920-4bf2-a1a8-f1404b513d8f" rel="noreferrer noopener">told</a> FT that he expected the demand to continue for at least ten years, citing their enormous return potential.
Tan stressed to the FT that clients were intensely ramping up AI infrastructure investment plans spanning three to five years.
He does not expect the phenomenon to lose steam until his clients run out of finances.
Last week, Tan told investors Broadcom <a target="_blank" href="https://www.benzinga.com//node/42488220" rel="noreferrer noopener">could generate</a> tens of billions of dollars in additional annual revenue from AI chips by 2027.
Tan&#8217;s experience and dealmaking prowess fuelled speculation of rescuing struggling chipmaker Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>). However, Tan claimed no hostile offers since 2018, when it was tracking Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), which succumbed to regulatory opposition.
Tan backed his thesis by citing investments by OpenAI and Elon Musk&#8217;s xAI in data centers in 2024.
Tan told the FT that its customers will build clusters of up to 1 million AI chips by 2027. However, Tan said that even 1 million chips may not suffice the AI ambitions of OpenAI and Anthropic.
Broadcom&#8217;s stock price rallied 24% in a single day last Friday after its AI revenues had surged by 220% in fiscal 2024. The chipmaker added over $200 billion to its market cap, breaching the $1 trillion milestone for the first time.
Rosenblatt&#8217;s Hans Mosesmann&nbsp;expects <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42489281/broadcoms-ai-chip-leadership-puts-pressure-on-nvidia-and-marvell-analysts-say" rel="noreferrer noopener">Broadcom&#8217;s growing moat</a> in expanding custom-chip (ASIC) AI and surging AI opportunities to intensify the rivalry with Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Nvidia. B of A Securities&#8216; Vivek Arya&nbsp;credited Broadcom with maintaining a position at customer Apple.
Investors can gain exposure to Broadcom through Amplify ETF Trust Amplify Cybersecurity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HACK#NYSE">HACK</a>) and First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>).
Price Action:&nbsp;AVGO stock closed lower by 2.37% at $218.32 Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>
Photo via Shutterstock

Tech

Media

AAPL

AVGO

GOOG

GOOGL

HACK

INTC

NVDA

QCOM

TDIV

Broadcom Expects Decade-Long AI Chip Boom as Big Tech Invest Billions

HC Wainwright &amp; Co. analyst Yi Chen reiterates Veru (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERU#NASDAQ">VERU</a>) with a Buy and maintains $3 price target.

VERU

HC Wainwright & Co. Reiterates Buy on Veru, Maintains $3 Price Target

ALSA

Alpha Star Acquisition Corporation Reveals Receipt Of Letter From Nasdaq Regarding Failure To Complete Initial Business Combination

Predictive Oncology, BIMI Holdings, IMAC Holdings among healthcare movers

INDO, IPDN and GSUN among mid-day movers

SBFM, BPTH and INDO among pre-market losers

ING, PALI and FNCH among pre-market losers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!



Earnings reports, an acquisition deal and more are behind today&rsquo;s biggest stock market movements.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Zhongchao (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) stock is rocketing 78% higher alongside heavy pre-market trading.</li>



<li>G1 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gthx-stock-quote/">GTHX</a>) shares are soaring more than 65% on <a href="https://finance.yahoo.com/news/pharmacosmos-group-acquire-g1-therapeutics-102900391.html">an acquisition deal</a>.</li>



<li>Richtech Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rr-stock-quote/">RR</a>) stock is surging over 48% with strong early morning trading.</li>



<li>AlphaVest Acquisition Corp &ndash; Right (NASDAQ:<a href="https://investorplace.com/stock-quotes/atmvr-stock-quote/">ATMVR</a>) shares are gaining more than 46% this morning.</li>



<li>Inogen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ingn-stock-quote/">INGN</a>) stock is increasing over 31% with its <a href="https://www.nasdaq.com/press-release/inogen-announces-second-quarter-2024-financial-results-2024-08-06">Q2 earnings report</a>.</li>



<li>Upstart (NASDAQ:<a href="https://investorplace.com/stock-quotes/upst-stock-quote/">UPST</a>) shares are rising more than 25% after <a href="https://finance.yahoo.com/news/upstart-holdings-inc-upst-reports-221010260.html">reporting a Q2 revenue beat</a>.</li>



<li>Lumen Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/lumn-stock-quote/">LUMN</a>) stock is heading over 24% higher <a href="https://www.fool.com/earnings/call-transcripts/2024/08/06/lumen-technologies-lumn-q2-2024-earnings-call-tran/">with its latest earnings</a>.</li>



<li>Veracyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcyt-stock-quote/">VCYT</a>) shares are climbing close to 22% after <a href="https://www.nasdaq.com/press-release/veracyte-announces-second-quarter-2024-financial-results-2024-08-06">announcing its Q2 results</a>.</li>



<li>Direxion Shares ETF Trust Direxion Daily Electric and Autonomous Vehicles Bull 2X Shares (NYSEARCA:<a href="https://investorplace.com/stock-quotes/evav-stock-quote/">EVAV</a>) are jumping more than 19% this morning.</li>



<li>Shopify (NYSE:<a href="https://investorplace.com/stock-quotes/shop-stock-quote/">SHOP</a>) stock is up 18% on <a href="https://za.investing.com/news/stock-market-news/shopify-stock-soars-on-solid-q2-report-issues-q3-guidance-432SI-3275444">solid Q2 earnings results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Scorpius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) shares are crashing over 79% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318500722&amp;type=PDF&amp;symbol=SCPX&amp;cdn=70e2821112bdd2f31adb78fe13cd4e38&amp;companyName=Scorpius+Holdings+Inc.&amp;formType=FWP&amp;formDescription=Filing+under+Securities+Act+Rules+163%2F433+of+free+writing+prospectuses&amp;dateFiled=2024-08-07">proposed public offering</a>.</li>



<li>Talis Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlis-stock-quote/">TLIS</a>) stock is plummeting more than 47% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318499549&amp;type=PDF&amp;symbol=TLIS&amp;cdn=2a3bd0b3e041ab6a71139ad061fc0a12&amp;companyName=Talis+Biomedical+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-08-06">on restructuring updates</a>.</li>



<li>DZS (NASDAQ:<a href="https://investorplace.com/stock-quotes/dzsi-stock-quote/">DZSI</a>) shares are diving over 45% as it <a href="https://www.nasdaq.com/press-release/dzs-receives-expected-delisting-notice-nasdaq-2024-08-06">prepares for a delisting notice</a>.</li>



<li>Stem (NYSE:<a href="https://investorplace.com/stock-quotes/stem-stock-quote/">STEM</a>) stock is tumbling 38% <a href="https://finance.yahoo.com/news/stem-inc-stem-reports-q2-221513320.html">on Q2 misses</a>.</li>



<li>Nevro (NYSE:<a href="https://investorplace.com/stock-quotes/nvro-stock-quote/">NVRO</a>) shares are taking a more than 37% beating after <a href="https://www.marketwatch.com/story/nevro-shares-fall-21-cuts-2024-revenue-outlook-75cf8aa9?mod=newsviewer_click">cutting its revenue outlook</a>.</li>



<li>Emergent BioSolutions (NYSE:<a href="https://investorplace.com/stock-quotes/ebs-stock-quote/">EBS</a>) stock is sliding over 35% <a href="https://www.stocktitan.net/news/EBS/emergent-bio-solutions-reports-second-quarter-2024-financial-h8fhmjurwquo.html">alongside its Q2 results</a>.</li>



<li>VBI Vaccines (NASDAQ:<a href="https://investorplace.com/stock-quotes/vbiv-stock-quote/">VBIV</a>) shares are dropping more than 34% <a href="https://investorplace.com/2024/08/why-is-vbi-vaccines-vbiv-stock-up-62-today/">after a rally yesterday</a>.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) stock is decreasing over 28% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318500633&amp;type=PDF&amp;symbol=XPON&amp;cdn=cc4a67ceca06cec716b8eaa852fb2069&amp;companyName=Expion360+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-08-06">with a public offering</a>.</li>



<li>Evotec (NASDAQ:<a href="https://investorplace.com/stock-quotes/evo-stock-quote/">EVO</a>) shares are falling more than 22% <a href="https://www.investing.com/news/stock-market-news/evotec-shares-crash-36-on-profit-warning-3558654">on a profit warning</a>.</li>



<li>CryoPort (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyrx-stock-quote/">CYRX</a>) stock closes out our pre-market stock movers down over 20% after <a href="https://finance.yahoo.com/news/cryoport-inc-cyrx-reports-q2-230011376.html">missing Q2 estimates</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-7th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Zhongchao&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/zcmd-stock-quote/">ZCMD</a>) stock is on the rise Wednesday alongside heavy pre-market trading of the healthcare information company&rsquo;s shares.



This has more than 12 million shares of ZCMD stock changing hands as of this writing. That&rsquo;s a massive leap over its daily average trading volume of about 58,000 shares. Investors will also note it has a low float <a href="https://finance.yahoo.com/quote/ZCMD/key-statistics/">at 1.29 million units</a>.



All of this movement comes without any clear news from Zhongchao. That includes a lack of press releases or filings with the Securities and Exchange Commission (SEC). There&rsquo;s also no analyst coverage that would cause the stock to rally today.



What is worth keeping in mind is ZCMD&rsquo;s status as a penny stock. This comes from its prior closing price of $1.09, low daily average trading volume and its market capitalization of only $2.748 million.



<h2>What That Means for ZCMD Stock</h2>



Being a penny stock opens Zhongchao&nbsp;shares up to certain vulnerabilities. Among these is volatility from heavy trading even with a lack of news.



It&rsquo;s possible this is tied to speculative traders buying the stock while its low. It could also be an attempt at a pump and dump by retail and day traders. One thing is for sure, traders will want to be careful about taking a stake in the company right now.



ZCMD stock is up 52% as of Wednesday morning.



There are more stock market stories investors need to know about below!



We have all of the hottest stock market news ready to go on Wednesday! That includes the biggest pre-market stock movers this morning and other news. All of that is available at the following links!



<h2>More Wednesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-7th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Wednesday</a></li>



<li><a href="https://investorplace.com/2024/08/trade-of-the-day-cinemark-cnk-stock-may-ride-higher-on-a-short-squeeze/">Trade of the Day: Cinemark (CNK) Stock May Ride Higher on a Short Squeeze</a></li>



<li><a href="https://investorplace.com/2024/08/nvidia-news-new-street-research-upgrades-nvda-stock-amid-selloff/">Nvidia News: New Street Research Upgrades NVDA Stock Amid Selloff</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-zhongchao-zcmd-stock-up-52-today/">Why Is Zhongchao (ZCMD) Stock Up 52% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Zhongchao (ZCMD) Stock Up 52% Today?

Zhongchao (ZCMD) has released an update. Zhongchao Inc., a Cayman Islands-based company, has just filed a registration statement with the U.S. Secu...

Zhongchao Inc. Readies Share Offering

Zhongchao (ZCMD) has released an update. Zhongchao Inc. reported a mixed financial performance for the first half of 2024, with total revenues decl...

Zhongchao Inc. Reports Mixed Financial Results for 2024

Zhongchao (ZCMD) has released an update. Zhongchao Inc., a Cayman Islands company, has issued a new Ordinary Shares Purchase Warrant, allowing hold...

Zhongchao Offers New Share Purchase Warrants

Zhongchao ( ($ZCMD) ) has provided an announcement. Zhongchao Inc. recently completed a private placement, issuing 10 million Class A ordinary shar...

Zhongchao Inc. Expands Equity Base Through Private Placement and Warrant Exercise

AEON

AGBA

ALLR

ATMVR

BACK

BIMI

CHRO

CYRX

CZOO

DCFC

DZSI

EDBL

EGOX

ENPH

EVAV

FNCH

GSUN

GTHX

HEPA

HUBC

INDO

INGN

INVO

IPDN

LUMN

MDIA

MNDR

NKGN

NURO

NVFY

NVRO

PAAS

PALI

POAI

RWOD

SBFM

SCPX

SERV

SHOP

SILO

SMCI

STEM

TLIS

TRSG

UPST

VBIV

VCYT

VZLA

XPON

YYAI

ZCMD

Press Releases

Zhongchao Inc. Announces 1-for-10 Share Consolidation

Zhongchao Inc. Announces Successful Medication Assistance Services for Over 7,000 SLE Patients with Approximately 130,000 Units of Medications

ATA Creativity Global - American Depositary Shares, each representing two common shares

ATA Creativity Glb

Amesite

Bright Scholar Education Holdings Limited American Depositary Shares, each representing four Class A Ordinary Share

Bright Scholar Education

Chegg

China Liberal Education Holdings Limited - Ordinary Shares

China Liberal Education

51Talk Online Education Group American depositary shares, each representing 60 Class A ordinary shares

51 Talk Online Education

Skillful Craftsman Education Technology Limited - Ordinary Share

Skillful Craftsman

EpicQuest Education Group International Limited - Common Stock

EpicQuest Education Group

Four Seasons Education (Cayman) Inc. American Depositary Shares, each ADS representing 10 ordinary shares

Four Seasons Education

Genius Gr

Golden Sun Health Technology Group Limited - Class A Ordinary Shares

Golden Sun Health

Visionary Holdings

Jiade

Jianzhi Education Technology Group Company Limited - American Depositary Shares

Jianzhi Education Tech

Legacy Education

Mynd.ai

Nerdy

NETCLASS TECHNOLOGY INC - Class A Ordinary Shares

Netclass Technology

QuantaSing Group Limited - American Depositary Shares

QuantaSing Group

Sunlands Technology Group American Depositary Shares, representing Class A ordinary shares

Comments

ZHONGCHAO

ZHONGCHAO (ZCMD) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL